Aspirin and Apixaban Combination for TIA Treatment

The American Heart Association/American Stroke Association recommends apixaban alone for patients with TIA and atrial fibrillation, without the addition of aspirin, as the combination significantly increases bleeding risk without proven benefit for stroke prevention 1
The 2021 AHA/ASA guidelines state that DOACs, including apixaban, are recommended over warfarin for patients with non-valvular atrial fibrillation and ischemic stroke or TIA, with a strength of evidence classified as high 1
Adding antiplatelet therapy to anticoagulation in atrial fibrillation patients increases bleeding risk without reducing stroke or MI compared to anticoagulation alone, with a strength of evidence classified as moderate 2

Evidence Against Combination Therapy

Combining anticoagulation with an antiplatelet agent does not reduce the risk of stroke or MI compared with anticoagulant therapy alone in AF patients, but there is definitive evidence of increased bleeding risk, with a strength of evidence classified as high 2
The combination of aspirin and clopidogrel with anticoagulation is classified as Class III: Harm, meaning it should be avoided unless there is a specific cardiac indication, with a strength of evidence classified as high 3
The only exception is if the patient has a concurrent acute coronary syndrome or recent coronary stent placement, which would require temporary dual antiplatelet therapy plus anticoagulation for a limited period, with a strength of evidence classified as moderate 3

If TIA is cardioembolic (atrial fibrillation), use apixaban alone, without adding aspirin, as target anticoagulation is sufficient for stroke prevention, with a strength of evidence classified as high 1, 2
If TIA is non-cardioembolic (atherothrombotic/lacunar), stop apixaban and switch to antiplatelet therapy, as anticoagulation is not recommended due to higher hemorrhagic risk, with a strength of evidence classified as moderate 1, 5

For patients with mechanical heart valves, add aspirin 75-100 mg daily to warfarin, but not apixaban, as DOACs are contraindicated, with a strength of evidence classified as high 1
For patients with recent acute coronary syndrome or coronary stent, temporarily add aspirin ± clopidogrel to apixaban for the minimum necessary duration, then discontinue antiplatelet therapy, with a strength of evidence classified as moderate 3

Do not reflexively add aspirin "for extra protection" as this is a common error that increases bleeding without benefit, with a strength of evidence classified as high 2, 3
Verify the TIA mechanism, as if the patient has atrial fibrillation, they should be on anticoagulation (apixaban), not aspirin, with a strength of evidence classified as high 1, 2
If the patient is on apixaban for atrial fibrillation but the TIA is actually non-cardioembolic, reconsider whether anticoagulation is the correct therapy, as antiplatelet therapy may be more appropriate, with a strength of evidence classified as moderate 5, 6